Prophylactic platelet transfusions: Which dose is the best dose? A review of the literature

Transfusion Medicine Reviews

Volumn 17, Issue 3, 2003, Pages 181-193

  Tinmouth, Alan T ^a   Freedman, John ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; BLEEDING; CLINICAL PRACTICE; DOSE CALCULATION; HUMAN; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; THROMBOCYTE TRANSFUSION;

EID: 0042845841     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-7963(03)00018-X     Document Type: Article

References (69)

1. Duke WW: The relation of blood platelets to hemorrhagic disease: description of a method for determining the bleeding time and coagualtion time and report of the three cases of hemorrhagic disease relieved by transfusion. JAMA 55:1185-1192, 1910
2. Sullivan MT, McCullough J, Schreiber GB, et al: Blood collection and transfusion in the United States in 1997. Transfusion 42:1253-1260, 2002
3. Surgenor DM, Wallace EL, Hao SH: Collection and transfusion of blood in the United States. N Engl J Med 322:1646-1651, 1990
4. Davey M: Trends in platelet utilization in Canada 1981-1987. Curr Stud Hematol Blood Transfus 54:89-93, 1988
5. Canadian Red Cross Society: Canadian Red Cross 1997-1998 Statistical Report, Ottawa, Canadian Red Cross Society, 1998
6. Pisciotto PT, Benson K, Hume H, et al: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 35:498-502, 1995
7. McCullough J, Steeper TA, Connelly DP, et al: Platelet utilization in a university hospital. JAMA 259:2414-2418, 1988
8. Goodnough LT, Ali S, Despotis G, et al: Economic impact of donor platelet count and platelet yield in apheresis products: Relevance for emerging issues in platelet transfusion therapy. Vox Sang 76:43-49, 1999
9. Kiss JE, Steer K, Triuzi DJ, et al: Transfusion response to standard dose and high-yield single donor platelets. Transfusion 33:4S, 1993 (abstr)
10. Benson K, Martinez S, Tolzmann L, et al: Split vs. whole apheresis platelets: clinical response in thrombocytopenic patients. Transfusion 36:4s, 1996 (abstr)
11. Chambers LA: Hospital survey of platelet transfusion practices: Component selection and dose. Transfusion 40:139s, 2000 (abstr)
12. Freireich TJ, Klimann A, Gaydos LA, et al: Response to repeated platelet transfusions from the same donor. Ann Intern Med 59:277-287, 1963
13. Djerassi I, Farber S, Evans AE: Transfusions of fresh platelet concentrates to patients with secondary thrombocytopenia. N Engl J Med 268:221-226, 1963
14. Han T, Stutzman L, Cohen E, et al: Effect of platelet transfusion on hemorrhage in patients with acute leukemia. An autopsy study. Cancer 19:1937-1942, 1966
15. Hersh E, Bodey G, Nies B: Causes of death in acute leukemia. JAMA 193:105-109, 1965
16. Higby DJ, Cohen E, Holland JF, et al: The prophylactic treatment of thrombocytopenic leukemic patients with platelets: A double blind study. Transfusion 14:440-466, 1974
17. Solomon J, Bofenkamp T, Fahey JL, et al: Platelet prophylaxis in acute non-lymphoblastic leukaemia. Lancet 1:267, 1978 (letter)
18. Murphy S, Litwin S, Herring LM, et al: Indications for platelet transfusion in children with acute leukemia. Am J Hematol 12:347-356, 1982
19. Gaydos LA, Freireich EJ, Mantel MA: The quantitative relationship between platelet count and hemorrhage in patients with acute leukemia. New Engl J Med 266:905-909, 1962
20. Beutler E: Platelet transfusions: The 20,000/microL trigger. Blood 81:1411-1413, 1993
21. Meyer R, Schiffer C: Platelet transfusion therapy for the cancer patient. Semin Oncol 17:198-209, 1990
22. Consensus conference: Platelet transfusion therapy. JAMA 257:1777-1780, 1987
23. Gmur J, Burger J, Schanz U, et al: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338:1223-1226, 1991
24. Fanning J, Hilgers RD, Murray KP, et al: Conservative management of chemotherapeutic-induced thrombocytopenia in women with gynecologic cancers. Gynecol Oncol 59:191-193, 1995
25. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, et al: Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 18:931-935, 1996
26. Navarro JT, Hernandez JA, Ribera JM, et al: Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Haematologica 83:998-1000, 1998
27. Heckman KD, Weiner GJ, Davis CS, et al: Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. Clin Oncol 15:1143-1149, 1997
28. Rebulla P, Finazzi G, Marangoni F, et al: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 337:1870-1875, 1997
29. Wandt H, Frank M, Ehninger G, et al: Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91:3601-3606, 1998
30. Schiffer CA, Dutcher JP, Aisner J, et al: A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 62:815-820, 1983
31. Williamson LM, Wimperis JZ, Williamson P, et al: Bedside filtration of blood products in the prevention of HLA alloimmunization - A prospective randomized study. Alloimmunisation Study Group. Blood 83:3028-3035, 1994
32. Murphy MF, Metcalfe P, Thomas H, et al: Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 62:529-534, 1986
33. Sniecinski I, O'Donnell MR, Nowicki B, et al: Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 71:1402-1407, 1988
34. Andreu G, Dewailly J, Leberre C, et al: Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 72:964-969, 1988
35. Carr R, Hutton JL, Jenkins JA, et al: Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 75:408-413, 1990
36. Gmur J, Burger J, Sauter C, Oelz O, et al: Alloimmunization by leukocyte-rich or leukocyte-poor random single donor platelets. Prog Clin Biol Res 337:45-48, 1990
37. van Marwijk Kooy M, van Prooijen HC, Moes M, et al: Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood 77:201-205, 1991
38. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al: Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: A randomized prospective study. Blood 85:824-828, 1995
39. Blundell EL, Pamphilon DH, Fraser ID, et al: A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion 36:296-302, 1996
40. Oksanen K, Kekomaki R, Ruutu T, et al: Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - A randomized trial. Transfusion 31:588-594, 1991
41. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 337:1861-1869, 1997
42. Goodnough LT: The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 40:1522-1527, 2001
43. Vamvakas EC: Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev 12:258-270, 1998
44. Ratko TA, Cummings JP, Oberman H, et al: Evidence-based recommendation for the use of WBC-reduced cellular blood components. Transfusion 41:1310-1319, 2001
45. Schiffer CA, Anderson KC, Bennett CL, et al: Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001
46. Contreras M: The appropriate use of platelets: an update from the Edinburgh Consensus Conference. Br J Haematol 101:10-12, 1998 (suppl 1)
47. Lawrence JB, Yomtovian RA, Hammons T, et al: Lowering the prophylactic platelet transfusion threshold: A prospective analysis. Leuk Lymphoma 41:67-76, 2001
48. Norfolk DR, Ancliffe PJ, Contreras M, et al: Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers. Br J Haematol 101:609-617, 1998
49. Roy A, Jaffe N, Djerassi I: Prophylactic platelet transfusions in children with acute leukemia: A dose response study. Transfusion 13:283-290, 1973
50. Menitove JE, Hertenstein EG, Tse LC: Decreasing platelet concentrate dose: Impact on platelet transfusion interval. Blood 88:333a, 1996 (abstr)
51. Goodnough LT, Kuter DJ, McCullough J, et al: Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 98: 1346-1351, 2001
52. Norol F, Bierling P, Roudot-Thoraval F, et al: Platelet transfusion: A dose-response study. Blood 92:1448-1453, 1998
53. Klumpp TR, Herman JH, Gaughan JP, et al: Clinical consequences of alterations in platelet transfusion dose: A prospective, randomized, double-blind trial. Transfusion 39:674-681, 1999
54. Kuter DJ, Goodnough LT, Romo J, et al: Thrombopoeitin therapy increases platelet yields in healthy platelet donors. Blood 98:1339-1345, 2001
55. Enright H, Gernsheimer T, Woodson RD, et al: Factors influencing the response to platelet transfusions. Blood 90:268a, 1997 (abstr)
56. Li J, Xia Y, Bertino A, et al: Characterization of an anti-thromboietin antibody that developed in a cancer patient following the injection of PEG-rHuMGDF. Blood 94:51a, 1999 (abstr)
57. Yang C, Xia Y, Li J, et al: The appearance of anti-thrombopoietin antibody and circulating thrombopoietin-IgG complexes in a patient developing thrombocytopenia after the injection of PEG-rHuMGDF. Blood 1999:681a, 1999 (abstr)
58. Slichter SJ, Harker LA: Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin Haematol 7:523-539, 1978
59. Muller-Eckhardt C, Muller-Eckhardt G, Kayser W, et al: Platelet associated IgG, platelet survival, and platelet sequestration in thrombocytopenic states. Br J Haematol 52:49-58, 1982
60. Hanson S, Slichter S: Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 66:1105-1109, 1985
61. Slichter SJ: Optimizing platelet transfusions in chronically thrombocytopenic patients. Semin Hematol 35:269-278, 1998
62. Hersh JK, Hom EG, Brecher ME: Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient. Transfusion 38:637-644, 1998
63. Baumann MA, Menitove JE, Aster RH, et al: Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med 104:808-809, 1986
64. Bautista AP, Buckler PW, Towler HM: Measurement of platelet life span in normal subjects and patients with myeloproliferative disease with indium oxine labelled platelets. Br J Haematol 1984:679-687, 1984
65. Brodsky I, Kahn SB, Ross EM, et al: Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders. Br J Haematol 30:1444-1450, 1972
66. Rees J, Slade RR, Hoopes P: Reduced platelet survival following chemotherapy with vinblastine, bleomycin and ciplatinum for testicular teratoma. Eur J Cancer Clin Oncol 18:1125-1129, 1982
67. Slichter SJ, Leblanc R, Jones MK, et al: Quantitaive analysis of bleeding risk in cancer patients prophylactically transfused at platelet counts of 5000, 10000, or 20000 platelets/uL. Blood 94:376a, 1999 (abstr)
68. Ackerman SJ, Klumpp TR, Guzman GI, et al: Economic consequences of alterations in platelet transfusion dose: Analysis of a prospective, randomized, double-blind trial. Transfusion 40:1457-1462, 2000
69. Cook DJ, Guyatt GH, Laupacis A: Clinical recomendations using levels of evidence for antithrombotic agents. Chest 108:227s-230s, 1995 (suppl)